MedPath

Effects omega-3 fatty acid supplementation in the treatment of diabetes

Phase 3
Conditions
Diabetic Nephropathy.
Glomerular disorders in diabetes mellitus (E10-E14 with common fourth character .2+)
N08.3
Registration Number
IRCT201504095623N41
Lead Sponsor
Kashan University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
60
Inclusion Criteria

Inclusion Criteria: Patients with diabetic nephropathy with FPG = 126 mg/dl less than 15 years of their disease aged 45 to 85 years.

Exclusion Criteria

The intake of omega-3 fatty acid supplements within the past 3 months
Uncontrolled diabetes mellitus
Current use of warfarin
Malignancy
Liver cirrhosis
Smoking

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Tumor Necrosis Factor alpha (TNFa). Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Elisa.;Receptor of Tumor Necrosis Factor alpha (TNFa). Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Elisa.
Secondary Outcome Measures
NameTimeMethod
Receptor of Advanced Glycation End Products. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Elisa.;Advanced Glycation End Products. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Fluorometeric method.
© Copyright 2025. All Rights Reserved by MedPath